are further exacerbated with age. The recent clinical study of reaZin
showed that the oral treatment is well-tolerated, and there are even trends to benefits in cognitive outcomes over the study period in several readouts. Based on the consistencies in these trends, the prevalence of abnormally low plasma zinc levels in the elderly, and the established detrimental effects of chronic zinc deficiency on cognition, I think it is very reasonable to test for the ability of reaZin
to ameliorate cognitive decline in a larger-scale clinical trial," said Ashley I. Bush, M.D., Ph.D., Head of the Oxidation Disorders Laboratory for the Mental Health Research Institute, University of Melbourne and Adeona Scientific Advisory Board member.
"It is well documented that zinc deficiency increases as we age, and we as well as other clinical groups have shown that Alzheimer's patients are more zinc deficient in comparison to age-matched control patients. These observations support our belief that the older an Alzheimer's patient is, the more zinc depleted that patient is, and therefore, it is likely that patient will receive greater cognitive benefit when managed with our proprietary zinc-based tablet," said George J. Brewer, M.D., Senior Vice President of Adeona. "As we are currently witnessing an epidemic of Alzheimer's disease, such that well over 10 million Americans are affected, we are very excited to begin a larger clinical study intended to further demonstrate that reaZin is effective in preventing or slowing the loss of cognition in older Alzheimer's patients and therefore help stem the tide of this epidemic."
Top-Line Results from the Clinical Study Evaluating reaZin
The top-line results from Adeona's clinical study evaluating reaZin for the dietary management of zinc deficiency associated with Alzheimer's disease were presented at the 63rd Annual Meeting of the American Academy of Neurology in April 2011.
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE Adeona Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller2
. Adeonas Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant3
. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results4
. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance5
. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL6256
. Anesiva Announces Second Quarter 2008 Financial Results and Update7
. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 20088
. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 20089
. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results10
. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results11
. ThirdBiotech Announces Kemeta as Newest Sponsor